PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access

puracath • Aug 03, 2021

Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting.

PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™Needleless Connector from the U.S. Food and Drug Administration (FDA). The Firefly™Needleless Connector is a sterile single patient use connector for needleless access to the IV line and IV catheter during IV therapy and can be used for direct injection, intermittent infusion, continuous infusion or aspiration. This regulatory determination by the FDA gives PuraCath clearance to market the FireFly™needleless connector in the U.S.

“Receiving 510(k) clearance for the FireFly™Needleless Connector is a major accomplishment for PuraCath™since it represents the initial regulatory approval in our vascular access product line,” said Julia Rasooly, PuraCath Medical’s CEO. “We believe our approach of using UV light to disinfect IV catheters in hospitals or in outpatient care will provide nurses and caregivers a safe and easy-to-use disinfection tool for reducing CLABSIs during infusions.”

“This is a major step toward eliminating practice variation with needleless connector asepsis,” stated Dr. Gregory Schears, anesthesiologist at Mayo Clinic, and Clinical Advisor to PuraCath™. “This will help ‘engineer in’ compliance and accountability which will further reduce CLABSI.”

PuraCath Medical™is planning a limited U.S. market release of the FireFly™Needleless Connector while it continues its initiatives to develop and commercialize additional safe, and user-friendly technologies in this product pipeline which are designed to reduce the risk of infectious complications (CLABSIs) associated with vascular access.

What is a CLABSI (Catheter-Line Associated Bloodstream Infection)?

A CLABSI (Catheter-Line Associated Bloodstream Infection) is a laboratory confirmed bloodstream infection related to a central line such as a central venous catheter, PICC line, midline, etc. CLABSIs are associated with a high-cost burden, accounting for approximately $46,000 per case, due to prolonged hospital stays and increased mortality. More than 250,000 CLABSIs are known to occur annually in the U.S. The most common cause of a CLABSI is due to improper aseptic techniques or lack of compliance to proper aseptic techniques, and improper management of the catheter lines during access.

About PuraCath Medical™

PuraCath Medical™, a Silicon Valley based-company, is dedicated to improving the quality of life of patients by reducing the risk of infections. The Company is utilizing its technology platform, which was spun out of Stanford University’s Biodesign program, to develop novel, easy-to-use devices designed to reduce the risk of infections in patients with catheters in order to decrease infection-related hospitalizations and their associated costs. PuraCath Medical™has received a prestigious small business government grant from the National Institute of Health (NIH) NIAID division with grant ID Number R43AI134553 and R44AI134553 to support these initiatives. 

For more information on PuraCath Medical™, please visit  http://www.puracath.com

Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath 16 Jun, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath 27 Apr, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2
By puracath 19 Mar, 2020
President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]
By puracath 19 Jun, 2019
JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]
By puracath 07 Mar, 2017
San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost 12 May, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost 28 Apr, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
PuraCath Medical Presents New Research Data during 36th Annual Dialysis Conference
By Larry Yost 29 Feb, 2016
Company presents study on the effectiveness of next-generation version of the FireFly™ Peritoneal Dialysis Connector Disinfecting System Seattle, Washington (February 29, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of […]
PuraCath Medical Receives 510(k) Clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecti
By puracath 26 Jan, 2016
PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it has received 510(k) clearance for its FireFly™ Peritoneal Dialysis Connector Disinfecting System from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives PuraCath clearance to market […]
By puracath 22 Oct, 2015
We are excited to announce that PuraCath Medical is listed as a start-up to watch in the latest volume of the MedTech Strategist published on October 16th.  Please read the full article here.
More Posts
Share by: